Compare AbCellera Biologics Inc (ABCL) vs Amer Sports Inc (AS) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Amer Sports (AS) trades at $34.84, down 0.6% on the day, with a neutral technical outlook. The company reported strong Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion. Analyst sentiment is overwhelmingly positive, with 12 of 14 analysts rating it a Buy and a consensus price target of $56.00, implying significant upside. Operating cash flow remains robust at $729.80 million for 2025.

The outlook is favorable given consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 43.54) and dependence on the Arc'teryx brand's sustained momentum. The stock presents a growth opportunity if execution continues, though premium valuation requires careful monitoring of margin trends and competitive pressures.